• Ovid Therapeutics named Kevin Norrett chief business officer to lead business development, corporate development, strategic partnerships.
• Norrett was chief business officer at Soleno Therapeutics, leading its acquisition by Neurocrine Biosciences; held executive roles at Codexis, Sierra Oncology.
• Charles Carter promoted to chief financial officer from SVP finance; succeeds Jeffrey Rona, who moves to an advisory role through 2027.
• Carter previously served as CFO of CERo Therapeutics, held finance and operational leadership roles across public and private life sciences companies.
• Eliseo Salinas joined as executive R&D advisor; Victoria Fort promoted to chief strategy officer from SVP corporate affairs and strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080700PRIMZONEFULLFEED9758783) on July 08, 2026, and is solely responsible for the information contained therein.